BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mosińska P, Storr M, Fichna J. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Therap Adv Gastroenterol 2015;8:278-84. [PMID: 26327918 DOI: 10.1177/1756283X15587866] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Su PY, Lee YH, Kuo LN, Chen YC, Chen C, Kang YN, Chang EH. Efficacy of AST-120 for Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:676345. [PMID: 34381357 DOI: 10.3389/fphar.2021.676345] [Reference Citation Analysis]
2 Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23(36): 6593-6627 [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6593] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
3 Chen H, Cao G, Chen DQ, Wang M, Vaziri ND, Zhang ZH, Mao JR, Bai X, Zhao YY. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol 2016;10:168-78. [PMID: 27750081 DOI: 10.1016/j.redox.2016.09.014] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 19.8] [Reference Citation Analysis]
4 van Kessel L, Teunissen D, Lagro-Janssen T. Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review. Int J Gen Med 2021;14:867-84. [PMID: 33758534 DOI: 10.2147/IJGM.S291964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]